Urine and Plasma Osmolality in Patients with Autosomal Dominant Polycystic Kidney Disease

Niek F. Casteleijn; Debbie Zittema; Stephan J. L. Bakker; Wendy E. Boertien; Carlo A. Gaillard; Esther Meijer; Edwin M. Spithoven; Joachim Struck; Ronald Gansevoort

doi:10.1159/000382081

Urine and Plasma Osmolality in Patients with Autosomal Dominant Polycystic Kidney Disease

Niek F. Casteleijn
, Debbie Zittema
, Stephan J. L. Bakker
, Wendy E. Boertien
, Carlo A. Gaillard
, Esther Meijer
, Edwin M. Spithoven
, Joachim Struck
, Ronald Gansevoort

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background: Vasopressin plays an essential role in osmoregulation, but has deleterious effects in patients with ADPKD. Increased water intake to suppress vasopressin activity has been suggested as a potential renoprotective strategy. This study investigated whether urine and plasma osmolality can be used as reflection of vasopressin activity in ADPKD patients. Methods: We measured urine and plasma osmolality, plasma copeptin concentration, total kidney volume (TKV, by MRI) and GFR (I-125-iothalamate). In addition, change in estimated GFR (eGFR) during follow-up was assessed. Results: Ninety-four patients with ADPKD were included (56 males, age 40 +/- 10, mGFR 77 +/- 32 ml/min/1.73 m(2), TKV 1.55 (0.99-2.40) l. Urine osmolality, plasma osmolality and copeptin concentration were 420 +/- 195, 289 +/- 7 mOsmol/l and 7.3 (3.2-14.6) pmol/l, respectively. Plasma osmolality was associated with copeptin concentration (R = 0.54, p

Original language	English
Pages (from-to)	248-256
Number of pages	9
Journal	American Journal of Nephrology
Volume	41
Issue number	3
DOIs	https://doi.org/10.1159/000382081
Publication status	Published - 2015
Externally published	Yes

Keywords

Autosomal dominant polycystic kidney disease
Urine osmolality
Plasma osmolality
Vasopressin
GLOMERULAR-FILTRATION-RATE
RENAL CONCENTRATING CAPACITY
SURROGATE MARKER
ARGININE-VASOPRESSIN
FUNCTION DECLINE
CYSTIC-DISEASE
COPEPTIN
WATER
PROGRESSION
TOLVAPTAN

Access to Document

10.1159/000382081

Cite this

@article{e8f2e120d60142d2a695f994f65c97e4,

title = "Urine and Plasma Osmolality in Patients with Autosomal Dominant Polycystic Kidney Disease",

abstract = "Background: Vasopressin plays an essential role in osmoregulation, but has deleterious effects in patients with ADPKD. Increased water intake to suppress vasopressin activity has been suggested as a potential renoprotective strategy. This study investigated whether urine and plasma osmolality can be used as reflection of vasopressin activity in ADPKD patients. Methods: We measured urine and plasma osmolality, plasma copeptin concentration, total kidney volume (TKV, by MRI) and GFR (I-125-iothalamate). In addition, change in estimated GFR (eGFR) during follow-up was assessed. Results: Ninety-four patients with ADPKD were included (56 males, age 40 +/- 10, mGFR 77 +/- 32 ml/min/1.73 m(2), TKV 1.55 (0.99-2.40) l. Urine osmolality, plasma osmolality and copeptin concentration were 420 +/- 195, 289 +/- 7 mOsmol/l and 7.3 (3.2-14.6) pmol/l, respectively. Plasma osmolality was associated with copeptin concentration (R = 0.54, p ",

keywords = "Autosomal dominant polycystic kidney disease, Urine osmolality, Plasma osmolality, Vasopressin, GLOMERULAR-FILTRATION-RATE, RENAL CONCENTRATING CAPACITY, SURROGATE MARKER, ARGININE-VASOPRESSIN, FUNCTION DECLINE, CYSTIC-DISEASE, COPEPTIN, WATER, PROGRESSION, TOLVAPTAN",

author = "Casteleijn, \{Niek F.\} and Debbie Zittema and Bakker, \{Stephan J. L.\} and Boertien, \{Wendy E.\} and Gaillard, \{Carlo A.\} and Esther Meijer and Spithoven, \{Edwin M.\} and Joachim Struck and Ronald Gansevoort",

year = "2015",

doi = "10.1159/000382081",

language = "English",

volume = "41",

pages = "248--256",

journal = "American Journal of Nephrology",

issn = "0250-8095",

publisher = "S. Karger AG",

number = "3",

}

TY - JOUR

T1 - Urine and Plasma Osmolality in Patients with Autosomal Dominant Polycystic Kidney Disease

AU - Casteleijn, Niek F.

AU - Zittema, Debbie

AU - Bakker, Stephan J. L.

AU - Boertien, Wendy E.

AU - Gaillard, Carlo A.

AU - Meijer, Esther

AU - Spithoven, Edwin M.

AU - Struck, Joachim

AU - Gansevoort, Ronald

PY - 2015

Y1 - 2015

N2 - Background: Vasopressin plays an essential role in osmoregulation, but has deleterious effects in patients with ADPKD. Increased water intake to suppress vasopressin activity has been suggested as a potential renoprotective strategy. This study investigated whether urine and plasma osmolality can be used as reflection of vasopressin activity in ADPKD patients. Methods: We measured urine and plasma osmolality, plasma copeptin concentration, total kidney volume (TKV, by MRI) and GFR (I-125-iothalamate). In addition, change in estimated GFR (eGFR) during follow-up was assessed. Results: Ninety-four patients with ADPKD were included (56 males, age 40 +/- 10, mGFR 77 +/- 32 ml/min/1.73 m(2), TKV 1.55 (0.99-2.40) l. Urine osmolality, plasma osmolality and copeptin concentration were 420 +/- 195, 289 +/- 7 mOsmol/l and 7.3 (3.2-14.6) pmol/l, respectively. Plasma osmolality was associated with copeptin concentration (R = 0.54, p

AB - Background: Vasopressin plays an essential role in osmoregulation, but has deleterious effects in patients with ADPKD. Increased water intake to suppress vasopressin activity has been suggested as a potential renoprotective strategy. This study investigated whether urine and plasma osmolality can be used as reflection of vasopressin activity in ADPKD patients. Methods: We measured urine and plasma osmolality, plasma copeptin concentration, total kidney volume (TKV, by MRI) and GFR (I-125-iothalamate). In addition, change in estimated GFR (eGFR) during follow-up was assessed. Results: Ninety-four patients with ADPKD were included (56 males, age 40 +/- 10, mGFR 77 +/- 32 ml/min/1.73 m(2), TKV 1.55 (0.99-2.40) l. Urine osmolality, plasma osmolality and copeptin concentration were 420 +/- 195, 289 +/- 7 mOsmol/l and 7.3 (3.2-14.6) pmol/l, respectively. Plasma osmolality was associated with copeptin concentration (R = 0.54, p

KW - Autosomal dominant polycystic kidney disease

KW - Urine osmolality

KW - Plasma osmolality

KW - Vasopressin

KW - GLOMERULAR-FILTRATION-RATE

KW - RENAL CONCENTRATING CAPACITY

KW - SURROGATE MARKER

KW - ARGININE-VASOPRESSIN

KW - FUNCTION DECLINE

KW - CYSTIC-DISEASE

KW - COPEPTIN

KW - WATER

KW - PROGRESSION

KW - TOLVAPTAN

U2 - 10.1159/000382081

DO - 10.1159/000382081

M3 - Article

SN - 0250-8095

VL - 41

SP - 248

EP - 256

JO - American Journal of Nephrology

JF - American Journal of Nephrology

IS - 3

ER -

Urine and Plasma Osmolality in Patients with Autosomal Dominant Polycystic Kidney Disease

Abstract

Keywords

Access to Document

Fingerprint

Cite this